
CORONAVIRUS DISEASE (COVID-19) PANDEMIC

Establishing a surveillance platform to assess the clinical impact of SARS-CoV-2 variants (DATCOV-Gen) in South Africa

Since the introduction of SARS-CoV-2 in the country in March 2020, South Africa has experienced three epidemic waves, with the Beta and Delta variants dominating the second and third waves, respectively. Genomic surveillance of SARS-CoV-2 in South Africa is currently being performed by the Network for Genomic Surveillance in South Africa (NGS-SA), which includes the NICD. NICD has established a prospective surveillance network linking real-time SARS-CoV-2 genomic sequencing data to detailed epidemiologic and clinical data on hospitalised cases to allow rapid assessment of severity and clinical presentation of SARS-CoV-2 variants of concern and future emerging lineages (DATCOV-Gen). Clinical specimens from COVID-19 cases are sent to the NICD from private and public diagnostic laboratories around the country (predominantly from Gauteng, North West, Mpumalanga and Northern Cape provinces), and collected through the pneumonia surveillance programme in five provinces (Western Cape, KwaZulu-Natal, North West, Gauteng and Mpumalanga). SARS-CoV-2 whole genomes are sequenced in real-time from a random selection of specimens, and are linked to epidemiological data through the notifiable medical conditions surveillance system (NMCSS), and clinical and outcome data through the DATCOV national surveillance system. DATCOV is an active surveillance system for COVID-19 hospital admissions with comprehensive coverage of all hospitals in South Africa.^{1,2}

From March 2020 through September 2021, 42 369 specimens were received at the NICD. Of these, 10 214 (24.1%) were sequenced and 6 673 (65.3%) yielded high quality sequence data for Global Initiative on Sharing All Influenza Data (GISAID) variant assignment (Figure 1). Among the sequenced cases, 1 272 (19.1%) were matched to hospitalised COVID-19 cases (hospital admission within 14 days of specimen collection) on the DATCOV database. The majority of specimens (1 158/1 272, 91%) were from adults aged \geq 25 years in Gauteng (36%), Western Cape (17%) and North West (16%) provinces (Table 1). Among the COVID-19 cases admitted to a hospital, presence of co-morbidity, level of hospital care, clinical severity and hospital admission duration differed by variant type. Further analysis of these data will enable us to better understand the epidemiological and clinical characteristics of SARS-CoV-2 variants, and this platform will allow these characteristics to be rapidly assessed as new variants emerge. Public and private testing laboratories are requested to continue to submit COVID-19 respiratory samples weekly to the NICD or their closest NGS-SA sequencing laboratory. For further information on specimen submission please contact Prof Anne von Gottberg (annev@nicd.ac.za), Dr Nicole Wolter (nicolew@nicd. ac.za) or the closest NGS-SA laboratory. Regular SARS-CoV-2 genomic surveillance and DATCOV reports are available on the NICD website.





CORONAVIRUS DISEASE (COVID-19) PANDEMIC

 Table 1: Epidemiological and clinical characteristics of hospitalised COVID-19 cases by SARS-CoV-2 variant type, DATCOV-Gen, March 2020 –

 September 2021

		Overall n (%)	Ancestral variants n (%)	Beta variant n (%)	Delta variant n (%)	P-value
Demographic characteristic	s					
Year		N=1 272	N=310	N=313	N=610	
	2020	266 (21)	192 (62)	74 (24)	0 (0)	<0.001
Foundation and the second	2021	1 006 (79)	118 (38) N=309	239 (76) N= 312	610 (100) N=610	
Epidemic wave ^a	Pre-wave 1	N=1 270 31 (2)	31 (10)	N=312 0 (0)	N=610 0 (0)	<0.001
	Wave 1	99 (8)	99 (32)	0 (0) 0 (0)	0 (0)	10.001
	Post-wave 1	56 (4)	51 (17)	5 (2)	O (O)	
	Wave 2	114 (9)	15 (5)	98 (31)	0 (0)	
	Post-wave 2	132 (10)	23 (7)	105 (34)	1 (0)	
	Wave 3	838 (66)	90 (29)	104 (33)	609 (100)	
	Nuve S	N=1 272	N=310	N=313	N=610	
Age group (years)	<5					0.364
		39 (3)	14 (5)	4 (1) 5 (0)	20 (3)	0.364
	5-12	13 (1)	2 (1)	5 (2)	6 (1)	
	13-18	24 (2)	5 (2)	8 (3)	11 (2)	
	19-24	38 (3)	11 (4)	7 (2)	19 (3)	
	25-39	180 (14)	45 (15)	45 (14)	83 (14)	
	40-59	424 (33)	104 (34)	93 (30)	216 (35)	
	≥60	554 (44)	129 (42)	151 (48)	255 (42)	
Sex		N=1 272	N=310	N=313	N=610	
	Male	538 (42)	137 (44)	134 (43)	256 (42)	0.727
	Female	734 (58)	173 (56)	179 (57)	357 (59)	
Province		N=1 272	N=310	N=313	N=610	
	Eastern Cape	93 (7)	44 (14)	12 (4)	37 (6)	<0.001
	Free State	1 (O)	O (O)	O (O)	1 (0)	
	Gauteng	453 (36)	100 (32)	173 (55)	158 (26)	
	KwaZulu-Natal	40 (3)	7 (3)	6 (2)	27 (4)	
	Limpopo	102 (8)	10 (3)	17 (5)	69 (11)	
	Mpumalanga	115 (9)	26 (8)	51 (16)	35 (6)	
	North West	209 (16)	77 (25)	20 (6)	109 (18)	
	Northern Cape	44 (3)	10 (3)	26 (8)	7 (1)	
	Western Cape	215 (17)	36 (12)	8 (3)	167 (27)	
Clinical characteristics						
HIV status	Uninfacted	N=564	N=170	N=111	N=266	0.710
	Uninfected	438 (78)	134 (79)	83 (75)	207 (78)	0.719
	Infected	126 (22)	36 (21)	28 (25)	59 (22)	
Co-morbidity		N=1 272	N=310	N=313	N=610	
	Absent	678 (53)	137 (44)	178 (57)	341 (56)	0.001
	Present	594 (47)	173 (56)	135 (43)	269 (44)	
Highest level of care		N=1 272	N=310	N=313	N=610	
	General ward	1 080 (85)	245 (79)	26 (83)	538 (88)	0.007
	High care	63 (5)	22 (7)	18 (6)	22 (4)	
	ICU	129 (10)	43 (14)	35 (11)	50 (8)	

CORONAVIRUS DISEASE (COVID-19) PANDEMIC

		Overall n (%)	Ancestral variants n (%)	Beta variant n (%)	Delta variant n (%)	P-value
Severe disease ^b		N=1 272	N=310	N=313	N=610	
	No	457 (36)	104 (34)	87 (28)	253 (41)	<0.001
	Yes	815 (64)	206 (66)	226 (72)	357 (59)	
Hospital duration (days)		N=1 266	N=310	N=312	N=606	
	<3	261 (21)	58 (19)	54 (17)	136 (22)	0.030
	3-6	410 (32)	100 (32)	90 (29)	209 (34)	
	7-13	408 (32)	103 (33)	107 (34)	188 (31)	
	≥14	187 (15)	49 (16)	61 (20)	73 (12)	
Outcome		N=1 266	N=310	N=312	N=606	
	Survived	928 (73)	235 (76)	219 (70)	449 (74)	0.258
	Died	338 (27)	75 (24)	93 (30)	157 (26)	

^a Epidemic wave periods (weekly incidence risk of ≥5 admissions per 100,000 individuals') defined as: Pre-wave 1 (weeks 10-23 of 2020), Wave 1 (weeks 24-34 of 2020), Post-wave 1 (weeks 35-46 of 2020), Wave 2 (week 47 of 2020) – week 5 of 2021), Post-wave 2 (weeks 6-19 of 2021), Wave 3 (20-38 of 2021). ^b Severe disease defined as a patient meeting at least one of the following criteria: admitted to ICU, received oxygen treatment, ventilated, received extracorporeal membrane oxygenation (ECMO), experienced acute respiratory distress syndrome (ARDS) and/or died.

References

- Jassat W, Mudara C, Ozougwu L, Tempia S, Blumberg L, Davies MA, Pillay Y, Carter T, Morewane R, Wolmarans M, von Gottberg A, Bhiman JN, Walaza S, Cohen C; DATCOV author group. Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. Lancet Glob Health. 2021 Sep;9(9):e1216-e1225. doi: 10.1016/S2214-109X(21)00289-8.
- Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, Murangandi P, Savulescu D, Walaza S, Bam JL, Davies MA, Prozesky HW, Naude J, Mnguni AT, Lawrence CA, Mathema HT, Zamparini J, Black J, Mehta R, Parker A, Chikobvu P, Dawood H, Muvhango N, Strydom R, Adelekan T, Mdlovu B, Moodley N, Namavhandu EL, Rheeder P, Venturas J, Magula N, Blumberg L; DATCOV author group. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. Lancet HIV. 2021 Sep;8(9):e554-e567. doi: 10.1016/S2352-3018(21)00151-X.

Acknowledgements

We thank all laboratories for submitting specimens for sequencing. Sequencing is performed as part of a larger network in South Africa (NGS-SA). Sequencing activities for NICD are supported by a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response; a cooperative agreement between the National Institute for Communicable Diseases of the National Health Laboratory Service and the United States Centers for Disease Control and Prevention (grant number 5 U01IP001048-05-00); the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub-award from the Bill and Melinda Gates Foundation grant number INV-018978; the UK Foreign, Commonwealth and Development Office and Wellcome (Grant no 221003/Z/20/Z); the South African Medical Research Council (Reference number SHIPNCD 76756); and the UK Department of Health and Social Care and managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project. The Fleming Fund is a £265 million UK aid programme supporting up to 24 low- and middle-income countries (LMICs) generate, share and use data on antimicrobial resistance (AMR) and works in partnership with Mott MacDonald, the Management Agent for the Country and Regional Grants and Fellowship Programme.